Vol 1, No 2 (2006)


Opinions of experts (№2, 2006 г.)

Genes & Cells. 2006;1(2):4-7
pages 4-7 views

Dear colleagues! (№2, 2006 г.)

Genes & Cells. 2006;1(2):8-8
pages 8-8 views
pages 9-9 views

Cell technology

pages 10-11 views
pages 11-12 views
pages 13-14 views

On the origin of fibroblast and its place in fibroblastic differon

Grigoryan A.S.
Genes & Cells. 2006;1(2):14-15
pages 14-15 views
pages 16-17 views

Controlled expansion of hematopoietic stem cells in vivo

Pospelov A.L.
Genes & Cells. 2006;1(2):17-18
pages 17-18 views

CD30 is a biomarker of transformed stem cells

Melikhova V.S.
Genes & Cells. 2006;1(2):19-19
pages 19-19 views

Isolation and characterization of melanoma stem cells

Melikhova V.S.
Genes & Cells. 2006;1(2):20-21
pages 20-21 views
pages 21-22 views
pages 22-23 views
pages 24-24 views
pages 25-26 views
pages 26-27 views
pages 27-27 views
pages 28-28 views


Sources of post-traumatic regeneration of the skin epithelium

Chepurnenko M.N.



Genes & Cells. 2006;1(2):29-31
pages 29-31 views

Artificial gametogenesis: differentiation of embryonic stem cells into gametes

Lopatina T.V.



Genes & Cells. 2006;1(2):32-34
pages 32-34 views


Postinfarction cellular regeneration therapy of the heart muscle

Kurtova A.V., Zueva E.E., Nemkov A.S.


Cellular regeneration therapy is a promising new way to treat diseases of the cardiovascular system. This review examines various experimental and clinical approaches to cell regeneration therapy, such as: local cytokine therapy, stimulation of the release of resident bone marrow stem cells and stem cell transplantation itself. The paper presents a detailed analysis of various types of donor cells used for cellular cardiomyoplasty in experimental and clinical studies. Particular attention is paid to the discussion of methods of cell delivery to the area of the damaged myocardium and methods of graft imaging.

Genes & Cells. 2006;1(2):35-43
pages 35-43 views

Prospects for the use of gene and cell therapy for the treatment of muscular dystrophy

Sukach A.N.


The review discusses modern approaches to the treatment of muscular dystrophy, a heterogeneous group of neuromuscular diseases that manifest themselves as progressive muscle weakness, as well as their partial loss, which in many cases leads to death. There are currently no effective medical methods for the treatment of dystrophies. However, there are several investigated therapeutic options for the treatment of muscular dystrophy, including gene therapy and transplantation of myogenic progenitor cells - cell therapy. The article discusses the achievements and difficulties on the way of introducing gene therapy into the clinical practice of treatment of muscular dystrophy. Special attention is paid to cell therapy, a promising direction of regenerative medicine, which gives hope for the cure of many previously incurable hereditary and acquired diseases. Potential sources of human somatic and embryonic stem/progenitor cells that can be used both as objects of application of genetic engineering methods and for cell therapy of muscular dystrophy are discussed. The problems that stand in the way of the successful introduction into clinical practice of the treatment of muscular dystrophy of human stem/progenitor cells are discussed.

Genes & Cells. 2006;1(2):44-50
pages 44-50 views

Original Study Articles

Bone marrow transplantation to mice with an experimental model of tuberculosis

Isaev A.A., Pospelov L.E., Bocharova I.V., Hegert V.Y., Stankov D.S., Prikhodko A.V., Avdienko V.G., Pospelov A.L.


The effectiveness of the use of bone marrow cells (CMC) in the treatment of experimental tuberculosis was investigated. It was shown that transplantation of allogeneic bone marrow cells from AKR mice resistant to tuberculosis to C57BL/6 mice sensitive to tuberculosis and infected with mycobacterium strain H37Rv significantly prolonged the life of infected experimental animals and reduced the number of mycobacteria seeded from organs compared with untreated animals. The study of humoral immunity showed that the introduction of allogeneic bone marrow cells leads to nonspecific polyisotypic stimulation of anti-tuberculosis antibodies, which is important in creating a protective humoral background. There was also a pronounced production of IgG2a antibodies in comparison with the level of IgG1 antibodies during therapy with bone marrow cells, which indicates the presence of a Tb1 response, which is clearly protective in tuberculosis. A high level of IgG2a antibodies correlated with a high level of a specific cellular immune response, assessed by a delayed-type hypersensitivity reaction (HRT).

Genes & Cells. 2006;1(2):51-54
pages 51-54 views

Are oval cells supposed to be liver stem cells or hepatoblasts?

Kiyasov А.P., Gumerova A.A., Titova M.A.


The aim of the work is to study the patterns of expression of oval cell markers during prenatal histogenesis of rat and human liver, as well as in human hepatocytes in vitro. The liver of rats was obtained at various gestation periods and during the first month after birth. Human embryos and fetuses are obtained as a result of legal medical abortions. The material was fixed and poured into paraffin according to the standard procedure or cryostatic sections were prepared, then stained with immunohistochemical indirect immunoperoxidase and streptavidin-biotin methods using commercial monoclonal antibodies to cytokeratins-7, -8, -18, -19. Gamma-glutamyl-transpeptidase was detected histochemically. The results of the studies showed that rat and human hepatoblasts express cytokeratin-19 and gamma-glutamyltrans-peptidase, whereas cholangiocytes express cytokeratin-7 (and only since the beginning of the formation of intrahepatic bile ducts). Moreover, human hepatocytes under cultivation begin to express cytokeratin-19 again. The data obtained show that the markers of oval cells (cytokeratin-19 and gamma-glutamyltranspeptidase) are markers of differentiating hepatocytes, which does not allow identifying oval cells with liver stem cells.

Genes & Cells. 2006;1(2):55-58
pages 55-58 views

The effect of severe polytrauma on the migration of hematopoietic stem cells in mice

Alexandrov V.N., Sergeev V.S.


It has been shown that hematopoietic stem cells (SCCS) are involved in the physiological and reparative regeneration of non-hematopoietic tissues and organs through transdifferentiation and/or cell fusion. In this regard, it seems interesting to evaluate the kinetics of bone marrow CCM in severe trauma. Three experimental models were used in the study: injury to mice followed by uneven irradiation in lethal doses with 1/2 shin screening (A), irradiation of mice in lethal doses followed by transplantation of bone marrow cells from injured mice (B), injury to mice followed by irradiation in sublethal doses (C). The migration of CCM was assessed by registering hematopoietic colonies growing on the spleen of irradiated mice from endo- or exogenous SCCS. In experimental models A and B, it was shown that a significantly larger number of endocolonies are formed in the spleens of injured mice in comparison with mice of control groups. In the experimental model B, it was shown that the bone marrow of injured mice contains a significantly smaller number of CCM capable of migration. Based on the results obtained, it was concluded that severe polytrauma induces CCM migration in mice.

Genes & Cells. 2006;1(2):59-62
pages 59-62 views

Discussion and general theoretical works

Lymphocytic control of hematopoietic stem cell differentiation

Manko V.M., Petrov R.V.


Nowadays, hundreds of experimental and clinical studies are devoted to the problems of stem cells [SC], both embryonic and tissue origin. Interest in this arose in connection with the comprehension and the possibility of reproducing two main qualities of SC: the ability to reproduce themselves for a long time and their multipotency, i.e. the ability to differentiate into any cell of the body. The first quality makes it possible to accumulate SC in culture. Secondly, it inspires with its allure the treatment of a very wide range of diseases, injuries, heart attacks, nervous and endocrine disorders, including diabetes. Tissue cloning removes all incompatibility problems during transplants.

Genes & Cells. 2006;1(2):63-75
pages 63-75 views

Research methods

Isolation of umbilical cord blood stem cells using an automatic functionally closed Sepax system

Kotus E.V.


Umbilical cord blood (PC) is used as a source of hematopoietic stem cells (HSCs) for transplantation in the treatment of a number of hematological and hereditary diseases.

Genes & Cells. 2006;1(2):76-77
pages 76-77 views

Stem Cells Business

Market analysis of cellular drugs for correction of skeletal tissue pathology

Deev R.V.


The article presents an overview of the main cellular preparations for the correction of skeletal tissues in the interests of patients with traumatic orthopedic and maxillofacial profile. The analysis of ways to create such drugs is carried out.

Genes & Cells. 2006;1(2):78-83
pages 78-83 views


Bibliography overview

Genes & Cells. 2006;1(2):84-86
pages 84-86 views
pages 87-88 views

Conference "Stem cells and prospects for their use in healthcare"

Potapov A.V.
Genes & Cells. 2006;1(2):89-90
pages 89-90 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies